• Publications
  • Influence
Combinatorial Strategies for the Induction of Immunogenic Cell Death
The term “immunogenic cell death” (ICD) is commonly employed to indicate a peculiar instance of regulated cell death (RCD) that engages the adaptive arm of the immune system. The inoculation ofExpand
  • 151
  • 8
  • PDF
Combinatorial Strategies for the Induction of Immunogenic Cell Death
1 Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France, 2 U1138, INSERM, Paris, France, Metabolomics and Cell Biology Platforms, GustaveExpand
  • 59
  • 7
  • PDF
Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
RNA interference (RNAi) is a specific gene-silencing mechanism that can be mediated by the delivery of chemical synthesized small-interfering RNA (siRNA). RNAi might constitute a novel therapeuticExpand
  • 153
  • 5
Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology
The identification of numerous deregulated signaling pathways on cancer cells and supportive stromal cells has revealed several molecular targets whose downregulation can elicit significant benefitsExpand
  • 21
  • 2
eIF2α phosphorylation is pathognomonic for immunogenic cell death
The phosphorylation of eIF2α is essential for the endoplasmic reticulum (ER) stress response, the formation of stress granules, as well as macroautophagy. Several successful anticancerExpand
  • 57
  • 1
Elimination of primary tumours and control of metastasis with rationally designed bacteriochlorin photodynamic therapy regimens.
Photodynamic therapy (PDT) with current photosensitisers focuses on local effects and these are limited by light penetration in tissues. We employ a stable near-infrared (NIR) absorbingExpand
  • 45
  • 1
Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.
The present work aimed at designing a lipid-based nanocarrier for siRNA delivery toward two cell sub-populations within breast tumors, the cancer and the endothelial cells from angiogenic tumor bloodExpand
  • 38
  • 1
Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Breast cancer stem cells (CSC) are thought responsible for tumor growth and relapse, metastization and active evasion to standard chemotherapy. The recognition that CSC may originate from non-stemExpand
  • 28
  • 1
Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
We have previously described the development of novel sterically stabilized F3-targeted pH-sensitive liposomes, which exhibited the ability to target both cancer and endothelial cells. Herein, theExpand
  • 22
  • 1
Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Drug resistance remains the Achilles tendon undermining the success of chemotherapy. It has been recognized that success requires the identification of compounds that, when combined, lead toExpand
  • 21
  • 1